Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 477

1.

Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.

Shen J, Zhang T, Cheng Z, Zhu N, Wang H, Lin L, Wang Z, Yi H, Hu M.

J Exp Clin Cancer Res. 2018 Jul 17;37(1):157. doi: 10.1186/s13046-018-0785-4.

2.

Quinazolinone-Amino Acid Hybrids as Dual Inhibitors of EGFR Kinase and Tubulin Polymerization.

Zayed MF, Rateb HS, Ahmed S, Khaled OA, Ibrahim SRM.

Molecules. 2018 Jul 12;23(7). pii: E1699. doi: 10.3390/molecules23071699.

3.

Revealing the molecular interactions of aptamers that specifically bind to the extracellular domain of HER2 cancer biomarker protein: An in silico assessment.

Niazi S, Purohit M, Sonawani A, Niazi JH.

J Mol Graph Model. 2018 Aug;83:112-121. doi: 10.1016/j.jmgm.2018.06.003. Epub 2018 Jun 6.

PMID:
29902673
4.

Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells.

Bach DH, Kim D, Bae SY, Kim WK, Hong JY, Lee HJ, Rajasekaran N, Kwon S, Fan Y, Luu TT, Shin YK, Lee J, Lee SK.

Mol Ther Nucleic Acids. 2018 Jun 1;11:455-467. doi: 10.1016/j.omtn.2018.03.011. Epub 2018 Mar 29.

5.

Asemeia ovata (Polygalaceae): Quantitative determination and evaluation in silico of identified substances by HPLC-DAD.

da Rocha JLC, da Silva DF, de Santana AR, da Costa DM, Pastore JFB, Alves CQ, Santos Junior MCS, Brandão HN.

Comput Biol Chem. 2018 Aug;75:65-73. doi: 10.1016/j.compbiolchem.2018.04.018. Epub 2018 Apr 30.

PMID:
29747077
6.

Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.

Yan Q, Chen Y, Tang B, Xiao Q, Qu R, Tong L, Liu J, Ding J, Chen Y, Ding N, Tan W, Xie H, Li Y.

Eur J Med Chem. 2018 May 25;152:298-306. doi: 10.1016/j.ejmech.2018.04.052. Epub 2018 Apr 27.

PMID:
29730192
7.

In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.

Patel H, Pawara R, Surana S.

Comput Biol Chem. 2018 Jun;74:167-189. doi: 10.1016/j.compbiolchem.2018.03.026. Epub 2018 Mar 29.

PMID:
29627693
8.

Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.

Dömötör O, Pelivan K, Borics A, Keppler BK, Kowol CR, Enyedy ÉA.

J Pharm Biomed Anal. 2018 May 30;154:321-331. doi: 10.1016/j.jpba.2018.03.011. Epub 2018 Mar 11.

PMID:
29567575
9.

Investigation of nepetolide as a novel lead compound: Antioxidant, antimicrobial, cytotoxic, anticancer, anti-inflammatory, analgesic activities and molecular docking evaluation.

Ur Rehman T, Khan AU, Abbas A, Hussain J, Khan FU, Stieglitz K, Ali S.

Saudi Pharm J. 2018 Mar;26(3):422-429. doi: 10.1016/j.jsps.2017.12.019. Epub 2017 Dec 28.

10.

Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.

Abdelatef SA, El-Saadi MT, Amin NH, Abdelazeem AH, Omar HA, Abdellatif KRA.

Eur J Med Chem. 2018 Apr 25;150:567-578. doi: 10.1016/j.ejmech.2018.03.001. Epub 2018 Mar 5.

PMID:
29549841
11.

In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 1.

Shi Z, Chen J, Guo X, Cheng L, Guo X, Yu T.

J Cancer Res Ther. 2018 Jan;14(1):18-23. doi: 10.4103/jcrt.JCRT_365_17.

12.

Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold.

Elzahabi HSA, Nossier ES, Khalifa NM, Alasfoury RA, El-Manawaty MA.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):546-557. doi: 10.1080/14756366.2018.1437729.

13.

Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs.

Zhang H, Wang J, Shen Y, Wang HY, Duan WM, Zhao HY, Hei YY, Xin M, Cao YX, Zhang SQ.

Eur J Med Chem. 2018 Mar 25;148:221-237. doi: 10.1016/j.ejmech.2018.02.051. Epub 2018 Feb 16.

PMID:
29466773
14.

Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study.

El-Husseiny WM, El-Sayed MA, Abdel-Aziz NI, El-Azab AS, Ahmed ER, Abdel-Aziz AA.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):507-518. doi: 10.1080/14756366.2018.1434519.

15.

6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.

Zhang Y, Chen L, Xu H, Li X, Zhao L, Wang W, Li B, Zhang X.

Eur J Med Chem. 2018 Mar 10;147:77-89. doi: 10.1016/j.ejmech.2018.01.090. Epub 2018 Feb 1.

PMID:
29421573
16.

Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.

Ding HW, Deng CL, Li DD, Liu DD, Chai SM, Wang W, Zhang Y, Chen K, Li X, Wang J, Song SJ, Song HR.

Eur J Med Chem. 2018 Feb 25;146:460-470. doi: 10.1016/j.ejmech.2018.01.081. Epub 2018 Jan 31.

PMID:
29407971
17.

Design, synthesis, mechanistic and histopathological studies of small-molecules of novel indole-2-carboxamides and pyrazino[1,2-a]indol-1(2H)-ones as potential anticancer agents effecting the reactive oxygen species production.

Youssif BGM, Abdelrahman MH, Abdelazeem AH, Abdelgawad MA, Ibrahim HM, Salem OIA, Mohamed MFA, Treambleau L, Bukhari SNA.

Eur J Med Chem. 2018 Feb 25;146:260-273. doi: 10.1016/j.ejmech.2018.01.042. Epub 2018 Jan 31.

PMID:
29407956
18.

The Design and Development of Potent Small Molecules as Anticancer Agents Targeting EGFR TK and Tubulin Polymerization.

Ihmaid S, Ahmed HEA, Zayed MF.

Int J Mol Sci. 2018 Jan 30;19(2). pii: E408. doi: 10.3390/ijms19020408.

19.

Antibodies as Carrier Molecules: Encapsulating Anti-Inflammatory Drugs inside Herceptine.

Cerón-Carrasco JP, Pérez-Sánchez H, Zúñiga J, Requena A.

J Phys Chem B. 2018 Feb 22;122(7):2064-2072. doi: 10.1021/acs.jpcb.7b10749. Epub 2018 Feb 8.

PMID:
29377693
20.

Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors.

Akula S, Kamasani S, Sivan SK, Manga V, Vudem DR, Kancha RK.

J Thorac Oncol. 2018 May;13(5):721-726. doi: 10.1016/j.jtho.2018.01.003. Epub 2018 Jan 31.

PMID:
29369805

Supplemental Content

Loading ...
Support Center